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Abstract
Purpose Does controlled ovarian stimulation (COS) and progesterone (P) luteal supplementation modify the vaginal and endo-
metrial microbiota of women undergoing in vitro fertilization?
Methods Fifteen women underwent microbiota analysis at two time points: during a mock transfer performed in the luteal phase
of the cycle preceding COS, and at the time of fresh embryo transfer (ET). A vaginal swab and the distal extremity of the ET
catheter tip were analyzed using next-generation 16SrRNA gene sequencing. Heterogeneity of the bacterial microbiota was
assessed according to both the Bray-Curtis similarity index and the Shannon diversity index.
Results Lactobacilluswas the most prevalent genus in the vaginal samples, although its relative proportion was reduced by COS
plus P supplementation (71.5 ± 40.6% vs. 61.1 ± 44.2%). In the vagina, an increase in pathogenic species was observed, involv-
ing Prevotella (3.5 ± 8.9% vs. 12.0 ± 19.4%), and Escherichia coli-Shigella spp. (1.4 ± 5.6% vs. 2.0 ± 7.8%). In the endometri-
um, the proportion of Lactobacilli slightly decreased (27.4 ± 34.5% vs. 25.0 ± 29.9%); differently, both Prevotella and
Atopobium increased (3.4 ± 9.5% vs. 4.7 ± 7.4% and 0.7 ± 1.5% vs. 5.8 ± 12.0%). In both sites, biodiversity was greater after
COS (p < 0.05), particularly in the endometrial microbiota, as confirmed by Bray-Curtis analysis of the phylogenetic distance
among bacteria genera. Bray-Curtis analysis confirmed significant differences also for the paired endometrium-vagina samples at
each time point.
Conclusions Our findings suggest that COS and P supplementation significantly change the composition of vaginal and endo-
metrial microbiota. The greater instability could affect both endometrial receptivity and placentation. If our findings are con-
firmed, they may provide a further reason to encourage the freeze-all strategy.
Keywords Microbiota . Vagina . Endometrium . IVF/IVF-ICSI . Controlled ovarian stimulation . Dysbiosis . Infertility .
Reproductive tract bacteria . Embryo implantation . 16S ribosomal subunit . Freeze all
Introduction
The microbiota of the female reproductive tract has long been
studied through cultivation methods to identify the
microorganisms that can be isolated and to assess their impact
on reproductive physiology. However, an accurate picture of
the microbial diversity in this body niche was achieved only
recently, following the advent of highly sensitive molecular
techniques that can identify microorganisms that cannot be
grown in culture [1]. Sequencing of the bacterial 16S ribosom-
al RNA (rRNA) gene, encoding an essential component of the
ribosome, is one of the most effective techniques in this field.
The rRNA gene has hypervariable regions (V1–V9) that can
be used to distinguish among even extremely similar, other-
wise undistinguishable, bacteria [2].
Next-generation sequencing (NGS) methods such as 16S
rRNA gene sequencing can be used to better define the bac-
terial community physiologically residing in the female repro-
ductive tract: mainly Lactobacilli but also a small proportion
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of Prevotella , Gardnerella , Atopobium , Sneathia ,
Bifidobacterium, Megasphaera, and Anaerococcus [3–5].
Bacteria in the vagina, endometrium, and follicular fluid
are likely to affect the reproductive process, from fertilization
to implantation, and frommaintenance of pregnancy to micro-
bial colonization of the newborn [6, 7]. With regard to in vitro
fertilization (IVF), the presence of certain bacterial strains in
the endometrium was reported to reduce the likelihood of
embryo implantation and, ultimately, the pregnancy rate [8,
9].
The physiological variability of ovarian steroid circulating
levels during the normal menstrual cycle was shown to induce
changes in vaginal microbiota [10]. It seems likely that the
progressive, supraphysiological increase in estradiol (E2) se-
rum levels during controlled ovarian stimulation (COS), as
well as the iatrogenic increase in progesterone (P) concentra-
tion resulting from luteal phase P supplementation, induces
significant changes in the vaginal and possibly also in the
endometrial microbiota. How these changes influence endo-
metrial receptivity toward embryo implantation is still largely
unknown. An estrogen (or progesterone)-induced alteration of
the vaginal and the endometrial microbiota could add a mi-
crobiological perspective to explain why implantation rates
are reportedly higher in frozen embryo-transfer (ET) cycles
vs. fresh ET following COS [11–13].
The aim of this pilot study was to investigate whether COS
and progesterone luteal phase supplementation in IVF patients
induce changes in the vaginal and the endometrial microbiota
that could potentially influence endometrial receptivity toward
embryo implantation. The changes were evaluated by using
both the Bray-Curtis similarity index and the Shannon index
to compare microbiota heterogeneity and stability in the two
sites before and after COS. Furthermore, variation in the con-
centration of the individual bacterial genera was assessed.
Materials and methods
Patients
The study was authorized by the local ethical committee (au-
thorization no. 0092218).
Fifteen patients undergoing IVF at the University
Reproductive Physiopathology Center of Sant’ Anna
Hospital, Turin were selected to participate in the study.
Inclusion criteria were Caucasian ethnicity, age ≤ 42 years,
basal (day 3) follicle-stimulating hormone (FSH) < 15 IU/l,
anti-müllerian hormone (AMH) > 0.2 ng/ml, regular menstru-
al cycles (25–32 days), no previous repeated implantation
failure (≥ 3 ETs of good scored embryos, with no pregnancy)
or recurrent miscarriage (> 3 previous first trimester miscar-
riages), absence of tubal or uterine pathology (e.g.,
hydrosalpinx, endometrial polyps, myomas), pPROM history,
and gastrointestinal disease. Patients receiving antibiotic or
probiotic therapy possibly interfering with endometrial and
vaginal microbiota were also excluded. Patients with a recent
history of cervico-vaginal infection were also excluded;
cervico-vaginal swabs were taken in all patients within
6 months prior to treatment. The swabs were analyzed by
sowing on CNA agar plates (nalidixic acid colistin) followed
by the MALDI-TOF technique for the identification of the
most common cervico-vaginal pathogens plus real-time PCR
for Chlamydia trachomatis, Neisseria gonorrhoeae,
Trichomonas vaginalis , Mycoplasma genital ium ,
Mycoplasma hominis , Ureaplasma parvum , and
Ureaplasma urealiticum.
Controlled ovarian stimulation and IVF
COS was accomplished using recombinant FSH (rFSH;
Gonal F®; Merck, Germany); the starting dose ranged be-
tween 100 and 300 IU/l and was tailored according to antral
follicle count (AFC), AMH, and body mass index (BMI,
weight in kg/height in m2). The initial rFSH daily dose was
eventually adjusted at the initial assessment of ovarian re-
sponse (day 6–7 of stimulation). Pituitary suppression was
achieved by administration of GnRH-antagonist cetrorelix
(Cetrotide®, Merck, Germany) according to a fixed protocol,
starting from day 6 of ovarian stimulation. COS was moni-
tored by serial transvaginal ultrasound (TV-US) plus serum
estradiol (E2) measurement starting on day 6–7 of COS, and
then every second day until at least two dominant follicles
reached 18 mm in diameter, with appropriate E2 levels. The
cycle was interrupted when nomore than one follicle > 10mm
in mean diameter was seen at US on day 6–7 and serum E2
was < 100 pg/ml. Final follicular maturation was triggered by
injecting subcutaneously 10,000 IU hCG (Gonasi HP®,
IBSA, Switzerland); TV-US-guided oocyte pick-up (OPU)
was performed approximately 36–37 h later under local anes-
thesia (paracervical block). Classical IVF or intracytoplasmic
sperm injection (ICSI) was performed according to clinical
indications. After 2 days of in vitro culture, embryos were
scored according to Holte et al. [14], and 1–2 embryos were
transferred in utero using a Guardia™ Access catheter (Cook
Medical®, Australia) under TV-US guidance, as previously
described [15]. Luteal phase supplementation was achieved
by administering 600 mg/day vaginal P (Progeffik®, Effik,
Belgium) for 14 days, starting the day of ET. Pregnancy was
assessed by serum hCG measurement 15 days after ET, and
then confirmed 2 weeks later if at least one gestational sac was
visualized at TV-US.
Microbiota analysis
Patients underwent vaginal and endometrial microbiota anal-
ysis at two time points: in the cycle preceding COS (pre-COS)
2316 J Assist Reprod Genet (2020) 37:2315–2326
and in the cycle in which COS, OPU, and ET were performed
(post-COS). For the pre-COSmicrobiota analysis, the patients
were asked to self-monitor ovulation every day at the same
time (first urine of the day) from day 10 of the cycle using a
commercial kit for LH peak detection in the urine (Clearblue®
Ovulation Test, Swiss Precision Diagnostics, Switzerland).
When the test turned positive, an outpatient appointment
was scheduled 3 days later to confirm spontaneous ovulation
by measuring circulating E2 and progesterone levels. On the
same day, a mock ET and a vaginal swab were performed: a
sterile speculum was inserted and a vaginal swab (Copan
eNat® COPAN Diagnostics, USA) was taken from the pos-
terior fornix. Immediately thereafter, ET was simulated using
a Guardia® Access catheter (Cook Medical®, Australia). The
catheter consists of two components: an outer guide and an
inner soft catheter; first, the guide is inserted into the cervical
canal, avoiding contact with the vaginal walls; the inner soft
catheter is then gently inserted into the guide and advanced
until reaching the endometrium inside the uterine cavity. The
inner catheter is protected from contact with the vagina or the
cervix by the outer guide. After retracting the catheter without
exposing its inner part to the vaginal environment, the distal
end of the inner part (approximately 5–10 mm) was cut using
sterile scissors and immediately placed in sterile PCR tubes.
To maintain the stability of bacterial DNA [16], vaginal and
endometrial samples were frozen at – 80 °C until analysis. An
ultrasound examination was performed at the end of the pro-
cedure to check for the presence of corpus luteum.
Post-COS microbiota analysis was performed in exactly
the same way at the time of fresh ET. A vaginal swab from
the posterior fornix was taken; then, ET was performed as
described, with the only difference that a medium droplet
containing 1–2 embryos was released about 1 cm from the
uterine fundus under TV-US guidance before retracting the
catheter, cutting the tip, and storing it.
16S ribosomal hypervariable region sequencing
Vaginal swabs and catheter tips underwent specific treatment
to obtain equal volumes for DNA extraction: 8 μl of sterile
deionized water was added to the catheter tip and 100 μl to the
swab. The samples were then gently vortexed to release the
bacteria into the solution. The first extraction step involved
digestion of the bacterial cell wall by adding 1 (catheter) or 2
(swab) μl of lysis buffer (200 mMKOH, 50 mM DTT). After
centrifugation, the solution was incubated at 65 °C for 10min;
1 (catheter) or 2 (swab) μl of neutralizing buffer (0.9 M Tris-
HCl, pH 8.3, 0.3 M KCl, 0.2 M HCl) was then added. The
extracted DNA was then purified: 10 μl of extract from the
swab and the solution from the catheter were recovered, and
20 μl of sterile deionized water and 54 μl of magnetic beads
(Agencourt® AMPure XP reagent, Beckman Coulter,
Thermo Fisher Scientific, USA) were added. The samples
were then incubated at room temperature for 5 min to allow
the magnetic beads to bind DNA and were then placed in a
DynaMag® (Thermo Fisher Scientific, USA) and washed
with 300 μl of 70% ethanol to eliminate the supernatant.
Both steps were repeated twice. A volume of 15 μl sterile
deionized water was added to recover the extracted and puri-
fied DNA; the pellet obtained after washing with ethanol was
re-suspended, and the samples were inserted again in the
DynaMag®; the supernatant was recovered, purified, and
stored at − 80 °C until sequencing.
Next-generation sequencing (NGS) of the bacteria-specific
16S ribosome gene was performed utilizing a microbiota so-
lution B kit—hypervariable regions V3-V4-V6 (Arrow
Diagnostics S.r.l., Italy). The B kit was composed of
Enzyme Mix 1 solution containing the enzyme mixture for
the PCR target, Enzyme Mix 2 solution containing the en-
zyme mixture for the PCR index, Amp Mix V3-V6 solution
of degenerated oligonucleotides for amplifying hypervariable
regions V3-V4-V6 of the bacterial 16S rDNA gene, and oli-
gonucleotide solution for indexing amplified samples with the
PCR target (IndexMix). An Illumina®MiSeq™ system plat-
form (Illumina Inc., USA) was used for sequencing. Raw
sequencing data have been uploaded to NCBI, project title:
BioProject PRJNA634237.
Taxonomic assignment and bioinformatic analysis were
performed using the MicrobAT® software (Microbiota
Analysis Tool; SmartSeq S.r.l., Italy). In the first phase of
the analysis, reads were cleaned by a dedicated algorithm to
remove short, low-quality sequences. Taxonomic assignment
was then made by aligning the remaining sequences with the
reference database (RDP database release 11-update 5) [17].
Only sequences that met reference criteria in the alignment
phase were associated by the analysis system to the species
taxonomic level (minimum length of the sequence aligning
with the reference sequence ≥ 80%, similarity percentage ≥
97%). The results were filtered by elimination of contaminat-
ing genera (Sphingomonas, Renibacterium, and Arthrobacter,
see Table 4), which were then detected by further analysis
performed using devices not in contact with biological
material.
Finally, the samples were characterized according to the
Shannon diversity index (SDI), and Bray-Curtis analysis of
the phylogenetic distance among genera was performed pre-
and post-COS for the vaginal and the endometrial sites.
Statistics
Statistical analysis was carried out with the R software® ver-
sion 3.4.2 (R Studio, USA). This version was extended with
the RAM package, designed for microbial ecology studies,
genomic, and metagenomic analysis; it is similar and equiva-
l en t t o o the r s (Vegan® , Ggp lo t2® , Labdsv®,
RColorBrewer®, and Heatplus®; https://www.rstudio.com).
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Quantitative variables were compared using the Wilcoxon
signed-rank test. Bray-Curtis distances were compared by
non-parametric analysis of similarities (ANOSIM). A p value
was derived based on the likelihood ratio test statistic for each
factor of interest. Significance was set at p < 0.05.
Results
Table 1 presents the patients’ baseline characteristics; all
womenwere spontaneously ovulating and had normal P levels
in the luteal phase of the cycle preceding COS.
Table 2 presents the outcome of the IVF cycle; the circu-
lating levels of E2 and P at ET (post-COS) were significantly
higher than the pre-COS levels (819.2 ± 187 vs. 135.3 ±
41.2 pg/ml for E2, post-COS, and pre-COS, respectively,
p < 0.05; 32.1 ± 7.4 vs. 11.5 ± 6.4 ng/ml for P, post-COS,
and pre-COS, respectively, p < 0.05) (Tables 1 and 2).
A total of 81 and 90 bacterial genera were isolated from the
vagina and the endometrium, respectively. Figure 1 shows the 30
most prevalent genera of the vaginal and the endometrial micro-
biota: In 13/15 patients (86.7%), a higher than 10% difference in
the pre-COS and post-COS bacterial composition of the micro-
biota (relevant for optimal taxonomic unit (OTU) classification
and relative abundance analysis) was detected. The pre-COS vs.
post-COS difference was very marked in some samples because
of the post-COS increase in potentially pathogenic genera, in-
cluding Atopobium, Gardnerella, and Pelomonas.
Table 3 lists the ten most prevalent bacterial genera (rela-
tive abundance analysis) in the vagina and the endometrium.
In the vaginal specimens, Lactobacillus was the most preva-
lent genus pre-COS and post-COS, although it was less abun-
dant in the post-COS vaginal swabs than before COS (71.5 ±
40.6% pre-COS vs. 61.1 ± 44.2% post-COS, respectively;
p > 0.05). An increase in pathogenic genera in the vaginal
microbiota was noted for Prevotella (3.5 ± 8.9% pre-COS
vs. 12.0 ± 19.4% post-COS, respectively; p > 0.05) and
Escherichia-Shigella (1.4 ± 5.6% pre-COS vs. 2.0 ± 7.8%
post-COS, respectively; p > 0.05) (Table 3).
The endometrial microbiota was extremely heterogeneous,
though Lactobacillus was the prevalent genus pre-COS and
remained the prevalent genus post-COS (27.4 ± 34.5% and
25.0 ± 29.9%, pre-COS and post-COS, respectively;
p > 0.05). An overall increase in the prevalence of potentially
pathogenic genera was observed post-COS: Prevotella was
significantly increased from 3.4 ± 9.5% to 4.7 ± 7.4% (p =
0.0494), and Atopobium was significantly increased from
0.7 ± 1.6% to 5.8 ± 12.0% post-COS (p = 0.0178).
Table 1 Baseline characteristics of patients. Values are expressed as
mean ± SD
Patient age (years) 35.1 ± 4.3
Partner age (years) 39.6 ± 5.4
Duration of infertility (years) 3.3 ± 1.0
BMI (kg/m2) 23.5 ± 4.4
Antral follicle count (AFC) 15.0 ± 4.3
AMH (ng/ml) 3.9 ± 2.4
Basal (day 3) FSH (IU/l) 6.1 ± 1.3
Estradiol (LH peak + 3 days, pre-COS; pg/ml) 135.3 ± 41.2
Progesterone (LH peak + 3 days, pre-COS; ng/ml) 11.5 ± 6.4
Sperm concentration (M/ml) 41.4 ± 25.7
Sperm progressive (A+B) motility (%) 26.0 ± 13.5
Sperm normal morphology (%) 10.1 ± 7.1
BMI body mass index; AMH anti-müllerian hormone; FSH follicle-
stimulating hormone
Table 2 IVF treatment outcome. Values are expressed as mean ± SD or
percentage
Daily exogenous FSH dose (IU)a 199.1 ± 43
Total exogenous FSH dose (IU)a 2467.2 ± 731
Peak estradiol at trigger (pg/ml) 2218.0 ± 1143
Progesterone at trigger (ng/ml) 0.7 ± 0.8
Retrieved oocytes 9.4 ± 5.5
Mature (MII) oocytes 8.0 ± 4.6
Fertilized (2PN) oocytes 5.7 ± 4.1
Cleaving embryos 5.6 ± 3.9
Mean embryo scoreb 7.6 ± 1.0
Number of embryos transferred 1.4 ± 0.9
Endometrial thickness at ET (mm)a 9.7 ± 1.7
Estradiol at ET (pg/ml) 819.2 ± 187
Progesterone at ET (ng/ml) 32.1 ± 7.4
Pregnancy rate/ET 46.6% (7/15)
aFSH follicle-stimulating hormone; ET embryo transfer
b Embryo score is expressed using the score by Holte et al., 2007
Fig. 1 Relative abundance of the 30 most present bacterial genera in the
vaginal and endometrial microbiota (pre-COS and post-COS). In each
line, pre refers to pre-COS analysis, post to post-COS analysis. Other
bacteria, not listed in the figure include Finegoldia, Curvibacter,
Ochrobactrum, Mobiluncus, Howardella, Bacteroides, Streptophyta,
Peptoniphilus , Ruminococcus , Alloscardovia , Paracoccus ,
Anaerosphaera, Caulobacter, Kocuria, Serratia, Neisseria, Ralstonia,
Parvimonas, Solobacterium, Enhydrobacter, Acinetobacter,
Enterococcus, Rothia, Granulicatella, Corynebacterium, Actinomyces,
Campylobacter, Fusobacterium, Bacillus, Slackia, Peptococcus,
Acidaminococcus, Oscillibacter, Saccharibacteria_genera_incertae_
sedis, Sutterella, Gp3, Cloacibacterium, Moryella, Gemmiger,
Spartobacteria_genera_incertae_sedis, Paenibacillus, Negativicoccus,
Propionimicrobium, Blautia, Faecalibacterium, Pedobacter,
Rhodococcus , Meiothermus , Allisonella , Carnobacterium ,
Lachnospiracea_incertae_sedis, Neochlamydia, Diaphorobacter,
Brevibacterium, Methylobacterium, Haemophilus, Micrococcus,
Azomonas, Clostridium_XVIII, Herbaspirillum, Oribacterium, Sarcina,
Nevskia
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Lactobacillus Gardnerella Prevotella Atopobium Veillonella Propionibacterium
Delftia Megasphaera Escherichia_Shigella Anaerococcus Pelomonas Bifidobacterium
Pseudomonas Porphyromonas Dialister Phyllobacterium Aerococcus Peptostreptococcus
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A comparison between the most prevalent 20 OTUs in the
vaginal and the endometrial samples at pre-COS and post-
COS analysis is shown in Fig. 2 a and b, respectively. The
slight degree of overlap in the two microbiota (gray part of the
columns) suggests a difference in the microbiota at both sam-
pling sites between pre- and post-COS analyses. Also, the
Shannon biodiversity index showed differences between pre-
COS and post-COS genera at both sampling sites (Fig. 3).
Biodiversity was greater in the endometrial microbiota at both
time points, indicating that vaginal and endometrial microbi-
ota had different characteristics (p < 0.05). In both sites, bio-
diversity was significantly greater after COS (p < 0.05), par-
ticularly in the endometrial microbiota, as confirmed by Bray-
Curtis analysis of the phylogenetic distance among bacteria
genera, which resulted significantly higher post-COS (Fig. 4 a
and b). Bray-Curtis analysis confirmed significant differences
also for the paired endometrium-vagina samples at each time
point (Fig. 4 c and d).
Discussion
Menstrual cycle phases and changes in circulating estrogen
levels over a woman’s lifespan are associated with changes
in the composition of vaginal microbiota [18, 19], but the
effect(s) of exogenous FSH administration, with the conse-
quent supraphysiological increase in E2, as well as P supple-
mentation in the luteal phase, have not been studied to date.
A similar knowledge gap exists for the endometrial micro-
biota. Until a few years ago, the uterine cavity was believed to
be sterile, and the presence of bacteria was associated with
pathological colonization by vaginal bacteria; rather recently,
it was demonstrated that the endometrium has its own micro-
biota and that the microbiological characteristics of the vagina
and the endometrium only partially overlap [8].
As ovarian steroids produced during the physiological
menstrual cycle affect vaginal microbiota, it seems plau-
sible that also the uterine microbiota could be influ-
enced by the fluctuations in E2 and P levels during
cycle phases; this hypothesis has never been investigat-
ed using advanced techniques, however. Similarly, the
impact of COS and P supplementation during IVF cy-
cles on vaginal and endometrial microbiota has never
been studied. Theoretically, the effects of ovarian ste-
roids on the composition of vaginal and endometrial
microbiota could be significantly amplified during COS
in comparison with the physiological menstrual cycle, as
COS induces wider and more rapid changes in E2 se-
rum levels than the natural cycle, while P supplementa-
tion after ET increases circulating P far beyond physio-
logical levels.
Based on these premises, the aim of the present study
was to evaluate the impact of COS and P supplementation
on vaginal and endometrial microbiota. The latter was
sampled using a previously described technique that avoids
contamination by vaginal flora [20]. Moreover, the vaginal
and the endometrial samples were submitted to a highly
sensitive, novel molecular methods (such as NGS of bac-
terial 16S RNA) for a thorough analysis of the bacterial
genera , b iodivers i ty , and microbia l ins tab i l i ty .
Unfortunately, the high costs of the NGS technique limited
the possibility of enrolling a larger patient population and
to relate microbiota composition to IVF outcome, an end-
point that was beyond the scope of this study.
We report for the first time data suggesting that COS
and P supplementation induce significant changes in the
vaginal and the endometrial microbiota at the time of the
so-called implantation window [21, 22] when fresh ET is
performed. The relative proportion of vaginal and endo-
metrial Lactobacillus was decreased during the IVF cycle
Table 3 Proportion of the 10
most abundant bacterial genera in
the vaginal and endometrial










Lactobacillus 71.5 ± 40.6 61.1 ± 44.2 27.4 ± 34.5 25.0 ± 29.9
Gardnerella 10.0 ± 19.2 6.5 ± 10.2 6.1 ± 13.5 10.1 ± 15.2
Prevotella 3.5 ± 8.9 12.0 ± 19.4 3.4 ± 9.5 4.7 ± 7.4*
Propionibacterium 0.1 ± 0.3 0.3 ± 0.6 11.5 ± 13.5 10.2 ± 8.9
Pseudomonas 0.0 ± 0.1 0.0 ± 0.1 10.3 ± 16.7 7.8 ± 12.7
Atopobium 5.7 ± 10.6 5.6 ± 9.4 0.7 ± 1.6 5.8 ± 12.0*
Delftia 0.5 ± 1.7 0.1 ± 0.3 6.0 ± 7.9 5.1 ± 7.7
Pelomonas 0.2 ± 0.7 0.1 ± 0.1 5.5 ± 5.4 5.4 ± 5.0
Veillonella 2.5 ± 6.7 2.8 ± 6.2 2.3 ± 6.2 1.6 ± 4.2
Escherichia coli/Shigella
spp.
1.4 ± 5.6 2.0 ± 7.8 2.5 ± 8.8 1.1 ± 2.7
Values are expressed as percentage ± SD
* p < 0.05 pre-COS vs. post-COS
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(post-COS), with a simultaneous increase in potentially
pathogenic bacteria, such as Atopobium, Escherichia-
Shigella, and Prevotella. An unfavorable change in the
vaginal and the endometrial microbiota after IVF (COS
and P supplementation) occurred: the increase in the mi-
crobial instability of the uterine cavity (higher Shannon
biodiversity index) was particularly pronounced.
This finding seems to contradict evidence that raising the
levels of circulating estrogen induces an increase in
Lactobacillus in the vagina [23, 24]. However, the estrogen
levels during ART treatment exceed by an order of magnitude
the natural levels during spontaneous ovulation, with
completely different kinetics depending on the type of COS.
The effects of these supraphysiological levels on vaginal and
endometrial microbiota have never been investigated so far.
However, whether or not these changes in the endometrial
microbiota might affect IVF outcome or increase the inci-
dence of obstetric complications is still unknown. Some au-
thors have criticized the hypothesis that endometrial microbi-
ota plays a role in IVF outcome [25] and a recently published
review [26] even questioned the existence of an active endo-
metrial microbiota. The conclusions of the review have been
challenged and critical issues raised [27], particularly as
regards the variations in endometrial microbiota composition
in relation to hormonal changes and compared with the vagi-
nal microbiota. The present study provides evidence in this
direction: the Shannon biodiversity index of the vaginal and
the endometrial samples differed before and after COS and the
biodiversity of the endometrial microbiota appeared to be












































































































































































































































































Endo Vag Endo & Vag
a
b
Fig. 2 Distribution of bacterial
genera in endometrial (blue part
of each column), vaginal (orange
part of each column), and
endometrial and vaginal (gray
part of each column) microbiota,
pre-COS (a) and post-COS (b).
Values are expressed as mean
number of reads
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a potential contamination effect of the pre-COS on the post-
COS analysis should be considered. However, the invasive-
ness of a vaginal swab and a transfer simulation is negligible,
so much so that it is routinely performed by some IVF centers.
Furthermore, a blank analysis of the devices used for the anal-
yses was carried out to exclude possible contaminants and









































































































































Fig. 3 Shannon values of vaginal and endometrial microbiota, pre-COS and post-COS
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their impact on subsequent analysis. It is unlikely, therefore,
that a minimal presence of bacteria, as identified in the blank
control (Table 4), could disrupt a microbiota dominated by
Lactobacilli in the time (about 1 month) between the two
analyses. Another potential contamination could have been
the self-administration of vaginal progesterone. Patients were
advised to wear sterile gloves during administration and our
analyses did not demonstrate a relevant presence of bacteria of
cutaneous origin in post-COS results. For these reasons, it is
reasonable to assume that the microbiota changes could be
COS-related.
Although Lactobacilluswas predominant in both, the pres-
ence of other bacteria and a more heterogeneous environment
compared with the vagina makes the endometrium an inter-
esting niche to explore.
Endometrial dysbiosis and subclinical chronic endometritis
have been claimed to be possible causes of repeated implan-
tation failure or recurrent miscarriage [28–30]. Furthermore,
the relative vaginal abundance of Atopobium, Escherichia-
Shigella, and Prevotella was associated with preterm delivery
[31] and a local pro-inflammatory state potentially affecting
placentation [32]. Also, IVF pregnancies are known to be
associated with a higher-than-normal risk of obstetrical com-
plications, including those of infectious origin (e.g., preterm
delivery, premature rupture of membranes) [33, 34].
Clarifying whether the endometrial microbiota after
COS might affect IVF outcome or not will be the objective
of our next study, taking into account the reportedly higher
implantation rate observed by some authors when, after the
so-called freeze-all strategy, thawed embryos are trans-
ferred in a cycle different from the one in which COS is
performed [35]. Indeed, in a natural cycle, when E2 and P
levels are physiological, the reported iatrogenic changes in
pre-COS endometrial microbiota would not occur, and em-
bryos could be transferred in a more physiological intra-
uterine environment.
Fig. 4 Analysis of the phylogenetic distance among bacterial genera
calculated by the Bray-Curtis method for the endometrium (a) and for
the vagina (b) and for the paired each type of sample, pre- and post-COS
(c, d). Color data points according to alpha diversity (Shannon index).
Connecting lines join the paired samples. The Bray-Curtis distance index
is calculated with the formula 1 − (2w/a + b), where w is the sum of the
minor score for species that are present in both communities, a is the sum
of the taxameasures in a community, and b is the sum of taxameasures in
the other community. The distance index was significantly increased
post-COS
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One limitation of the present study is the small study
sample size (n = 15). Nonetheless, analysis of four sam-
ples from the same patient, taken at two sites and at
different time points in IVF treatment, makes this study
one of the few with a highly detailed characterization of
intra-individual variability of the microbiota of the fe-
male reproductive tract. This is a fundamental theme in
the study of microbiota. Indeed, frequent fluctuations in
the composition of vaginal microbiota have been docu-
mented by microscopy and cultivation studies [36–38].
Fluctuations can be triggered by genetic predisposition
in different ethnic groups, menstruation or sexual behav-
iors, and a history of bacterial vaginosis or be driven by
uncharacterized factors, especially in not Lactobacillus-
dominated microbiota [39]. Although we have tried to
limit these factors (Caucasian ethnicity, exclusion of pa-
tients with cervico-vaginal infections in the last
6 months), intra-individual variability in microbiota
study remains a factor to be taken into account, and
the results should be interpreted with caution.
Further research into the impact of the microbiota on repro-
duction should be focused in this direction. For example, it is
necessary to integrate information on the female microbiota
with that of seminal fluid, which has its own microbiota [40,
41]. Indeed, it is likely that in the future our attention will shift
from studying the individual microbiota to the “reproductive
microbiota” of the couple. In this view, it will be interesting to
integrate the impact of the “bacterial microbiota” with that of
the “virota,” which together can potentially impact IVF out-
comes, as recently demonstrated [42].
Furthermore, it will be of pivotal importance to define the
characteristics of the endometrial microbiota and understand its
physiological alterations during the menstrual cycle. These pre-
mises are fundamental to fully understand the potential repercus-
sions of the microbiota on implantation and also on the evolution
of pregnancy. Clinicians must be aware of the fluctuations of the
reproductive microbiota in order to identify the transitory condi-
tions that can be associated with better reproductive and obstetric
outcomes.
In conclusion, our pilot study shows for the first time with
NGS of the 16S ribosomal subunit that COS and P supple-
mentation routinely performed during IVF treatment induce
unfavorable changes in the composition of vaginal and endo-
metrial microbiota, increasing the proportion of potentially
pathogenetic genera at both sites and significantly increasing
the biodiversity and the environmental instability of the uter-
ine cavity during the so-called implantation window.
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